Different immune contextures underlie tumor site‐specific responses to immune checkpoint blockade in esophageal cancer-Reference-Cited by-同舟云学术

Different immune contextures underlie tumor site‐specific responses to immune checkpoint blockade in esophageal cancer

Published:2023-06-20 Issue:22 Volume:14 Page:2216-2221
ISSN:1759-7706
Container-title:Thoracic Cancer
language:en
Short-container-title:Thoracic Cancer

Author:

Guo Jhe‐Cyuan¹²³^ORCID,Hsu Chia‐Lang⁴⁵,Hsieh Min‐Shu⁶,Lin Chia‐Chi¹²³,Huang Ta‐Chen³⁵,Kuo Hung‐Yang³⁵,Shao Yu‐Yun³⁵,Hsu Chih‐Hung¹³⁵^ORCID

Affiliation:

1. Department of Medical Oncology National Taiwan University Cancer Center Taipei Taiwan

2. Graduate Institute of Clinical Medicine National Taiwan University College of Medicine Taipei Taiwan

3. Department of Oncology National Taiwan University Hospital Taipei Taiwan

4. Department of Medical Research National Taiwan University Hospital Taipei Taiwan

5. Graduate Institute of Oncology National Taiwan University College of Medicine Taipei Taiwan

6. Department of Pathology National Taiwan University Cancer Center Taipei Taiwan

Abstract

AbstractImmune checkpoint inhibitors (ICIs) have demonstrated efficacy in advanced esophageal squamous cell carcinoma (ESCC). Heterogeneous responses to ICIs have been reported previously. Here, we describe a patient with advanced ESCC exhibiting a response to durvalumab plus tremelimumab for more than 6 months except primary resistant esophageal tumor. The esophageal tumor had higher regulatory T cells, neutrophils, and mast cells scores estimated by NanoString platform than hepatic tumor. The immunohistochemistry study confirmed higher expression levels of Foxp3, and myeloperoxidase (MPO) in the esophageal tumor. The different immune contextures may underlie the heterogeneous responses to ICI combination in this ESCC patient.

Funder

Ministry of Health and Welfare

Ministry of Science and Technology, Taiwan

Publisher

Wiley

Subject

Pulmonary and Respiratory Medicine,Oncology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/1759-7714.14997

Reference14 articles.

1. Postchemoradiotherapy Pathologic Stage Classified by the American Joint Committee on the Cancer Staging System Predicts Prognosis of Patients with Locally Advanced Esophageal Squamous Cell Carcinoma

2. Anti-PD-1 immunotherapy in advanced esophageal squamous cell carcinoma: A long-awaited breakthrough finally arrives

3. Embracing anti-PD-1 immunotherapy in the treatment of esophageal cancer: Implications of positive phase III trials in advanced and resected esophageal cancer

4. Patterns of response to anti-PD-1 treatment: an exploratory comparison of four radiological response criteria and associations with overall survival in metastatic melanoma patients

5. Response to Immune Checkpoint Inhibitors in Recurrent or Metastatic Esophageal Squamous Cell Carcinoma May Be Affected by Tumor Sites